OTLK (Outlook Therapeutics) E10: $-121.77 (As of Mar. 2026)


OTLK Outlook Therapeutics Inc OTLK
11 GF Score
Price $1.73
! 6 Warning Signs
View Full Analysis

What is Outlook Therapeutics E10?

Outlook Therapeutics OTLK +6.21% 11 E10 is $-121.77 as of Mar. 2026. GuruFocus rates OTLK with a GF Score™ of 11/100. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Outlook Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.050. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-121.77 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-27), Outlook Therapeutics's current stock price is $1.7299. Outlook Therapeutics's E10 for the quarter that ended in Mar. 2026 was $-121.77. Outlook Therapeutics's Shiller PE Ratio of today is .


Outlook Therapeutics  (NAS:OTLK) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Outlook Therapeutics E10 Related Terms


Outlook Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Outlook Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics E10 Chart

Outlook Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -220.59 -150.13

Outlook Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -191.62 -175.44 -150.13 -123.86 -121.77

OTLK vs INO, CBUS, RANI: E10 Comparison

For the Biotechnology subindustry, Outlook Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Outlook Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's Shiller PE Ratio falls into.


OTLK
11GF Score
Outlook Therapeutics Inc OTLK
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Outlook Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Outlook Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.05/330.2130*330.2130
=-0.050

Current CPI (Mar. 2026) = 330.2130.

Outlook Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201606 -256.000 241.018 -350.739
201609 -38.400 241.428 -52.522
201612 -131.200 241.432 -179.446
201703 -60.800 243.801 -82.350
201706 -35.200 244.955 -47.452
201709 -48.000 246.819 -64.218
201712 -113.600 246.524 -152.164
201803 -53.200 249.554 -70.395
201806 -42.000 251.989 -55.038
201809 -28.025 252.439 -36.659
201812 -20.000 251.233 -26.287
201903 -19.600 254.202 -25.461
201906 -4.000 256.143 -5.157
201909 -7.171 256.759 -9.222
201912 -12.400 256.974 -15.934
202003 -7.200 258.115 -9.211
202006 -0.600 257.797 -0.769
202009 -1.560 260.280 -1.979
202012 -2.400 260.474 -3.043
202103 -1.800 264.877 -2.244
202106 -1.400 271.696 -1.702
202109 -1.600 274.310 -1.926
202112 -1.600 278.802 -1.895
202203 -1.800 287.504 -2.067
202206 -1.600 296.311 -1.783
202209 -1.200 296.808 -1.335
202212 -1.600 296.797 -1.780
202303 -0.520 301.836 -0.569
202306 -1.610 305.109 -1.742
202309 -0.990 307.789 -1.062
202312 -0.860 306.746 -0.926
202403 -8.010 312.332 -8.469
202406 -0.890 314.175 -0.935
202409 0.760 315.301 0.796
202412 0.720 315.605 0.753
202503 -1.500 319.799 -1.549
202506 -0.550 322.561 -0.563
202509 -0.190 324.800 -0.193
202512 -0.380 324.054 -0.387
202603 -0.050 330.213 -0.050

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-121.77 mean?
Outlook Therapeutics (OTLK) has a E10 of $-121.77 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Outlook Therapeutics and its competitors.
Is Outlook Therapeutics' E10 too high?
Outlook Therapeutics' current E10 is $-121.77. Overall, Outlook Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' E10 compare to INO and CBUS?
Outlook Therapeutics' E10 of $-121.77 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Outlook Therapeutics and its competitors. Outlook Therapeutics's current E10 is $-121.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current E10 of $-121.77. The current E10 is $-121.77. Outlook Therapeutics' overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current E10 is $-121.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Outlook Therapeutics Business Description

Other Exchanges 41O:Germany
Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
11GF Score

Get the complete analysis for OTLK

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.73
Price